For: | Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21(13): 3777-3785 [PMID: PMC4385525 DOI: 10.3748/wjg.v21.i13.3777] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i13/3777.htm |
Number | Citing Articles |
1 |
Eduardo Castillo‐Leon, Catherine E. Cioffi, Miriam B. Vos. Perspectives on youth‐onset nonalcoholic fatty liver disease. Endocrinology, Diabetes & Metabolism 2020; 3(4) doi: 10.1002/edm2.184
|
2 |
Arata Banno, Mako Yamamoto, Maihemuti Mijiti, Asahi Takeuchi, Yuyang Ye, Natsuki Oda, Nanami Nishino, Akio Ebihara, Satoshi Nagaoka. The physiological blood concentration of phenylalanine-proline can ameliorate cholesterol metabolism in HepG2 cells. Bioscience, Biotechnology, and Biochemistry 2022; 87(1): 90 doi: 10.1093/bbb/zbac167
|
3 |
Weijia Lu, Yanqiu Zhang, Yawei Li, Shengtao Ye, Jun Luo, Lingyi Kong, Wenjun Xu. Hyperbenzones A and B, two 1,2-seco and rearranged polycyclic polyprenylated acylphloroglucinols from Hypericum beanii. Chinese Chemical Letters 2022; 33(8): 4121 doi: 10.1016/j.cclet.2021.11.011
|
4 |
Rifaat Safadi, Marius Braun, Adi Francis, Yael Milgrom, Muhammad Massarwa, David Hakimian, Wadi Hazou, Assaf Issachar, Zivit Harpaz, Motti Farbstein, Inbal Itzhak, Naama Lev‐Cohain, Avital Bareket‐Samish, Michael H. Silverman, Pnina Fishman. Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis. Alimentary Pharmacology & Therapeutics 2021; 54(11-12): 1405 doi: 10.1111/apt.16664
|
5 |
Yue Yu, Shu-Ming Ye, De-Yun Liu, Li-Qi Yang. AP39 ameliorates high fat diet-induced liver injury in young rats via alleviation of oxidative stress and mitochondrial impairment. Experimental Animals 2021; 70(4): 553 doi: 10.1538/expanim.21-0056
|
6 |
Luciana M. A. Borém, João F. R. Neto, Igor V. Brandi, Deborah F Lelis, Sergio H. S. Santos. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertension Research 2018; 41(6): 394 doi: 10.1038/s41440-018-0040-6
|
7 |
Varsha D. Shiragannavar, Nirmala G. Sannappa Gowda, Lakshana D. Puttahanumantharayappa, Shreyas H. Karunakara, Smitha Bhat, Shashanka K. Prasad, Divya P. Kumar, Prasanna K. Santhekadur. The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1135952
|
8 |
Mohamed Kamal Shaker, Mohamed Hassany, Basem Eysa, AbdulMoneim Adel, Ahmed Zidan, Shahnaz Mohamed. The activity of a herbal medicinal product of Phyllanthus niruri and Silybum marianum powdered extracts (Heptex®) in patients with apparent risk factors for nonalcoholic steatohepatitis: a phase II, multicentered, randomized, double-blind, placebo-controlled clinical trial. BMC Complementary Medicine and Therapies 2025; 25(1) doi: 10.1186/s12906-024-04692-y
|
9 |
Komal Thapa, Ajmer Singh Grewal, Neha Kanojia, Lata Rani, Neelam Sharma, Sukhbir Singh. Alcoholic and Non-Alcoholic Liver Diseases: Promising Molecular Drug Targets and their Clinical Development. Current Drug Discovery Technologies 2021; 18(3): 333 doi: 10.2174/1570163817666200121143959
|
10 |
Rong Zhang, Keran Cheng, Shizan Xu, Sainan Li, Yuqing Zhou, Shunfeng Zhou, Rui Kong, Linqiang Li, Jingjing Li, Jiao Feng, Liwei Wu, Tong Liu, Yujing Xia, Jie Lu, Chuanyong Guo, Yingqun Zhou. Metformin and Diammonium Glycyrrhizinate Enteric-Coated Capsule versus Metformin Alone versus Diammonium Glycyrrhizinate Enteric-Coated Capsule Alone in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Gastroenterology Research and Practice 2017; 2017: 1 doi: 10.1155/2017/8491742
|
11 |
Mi Ra Lee, Hye Jin Yang, Kwang Il Park, Jin Yeul Ma. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice. Phytomedicine 2019; 55: 14 doi: 10.1016/j.phymed.2018.07.008
|
12 |
Zhe Zhang, Hui Zhou, Meiyu Guan, Xiaohong Zhou, Xi Liang, Youyou Lv, Lu Bai, Junxue Zhang, Pimin Gong, Tongjie Liu, Huaxi Yi, Jingfeng Wang, Lanwei Zhang. Lactobacillus casei YRL577 combined with plant extracts reduce markers of non-alcoholic fatty liver disease in mice. British Journal of Nutrition 2021; 125(10): 1081 doi: 10.1017/S0007114520003013
|
13 |
Yuanjun Deng, Maoxing Pan, Huan Nie, Chuiyang Zheng, Kairui Tang, Yupei Zhang, Qinhe Yang. Lipidomic Analysis of the Protective Effects of Shenling Baizhu San on Non-Alcoholic Fatty Liver Disease in Rats. Molecules 2019; 24(21): 3943 doi: 10.3390/molecules24213943
|
14 |
Eunsook S. Jin, A. Dean Sherry, Craig R. Malloy. An Oral Load of [13C3]Glycerol and Blood NMR Analysis Detect Fatty Acid Esterification, Pentose Phosphate Pathway, and Glycerol Metabolism through the Tricarboxylic Acid Cycle in Human Liver. Journal of Biological Chemistry 2016; 291(36): 19031 doi: 10.1074/jbc.M116.742262
|
15 |
Maddalena Parafati, Antonella Lascala, Daniele La Russa, Chiara Mignogna, Francesca Trimboli, Valeria Maria Morittu, Concetta Riillo, Rachele Macirella, Vincenzo Mollace, Elvira Brunelli, Elzbieta Janda. Bergamot Polyphenols Boost Therapeutic Effects of the Diet on Non-Alcoholic Steatohepatitis (NASH) Induced by “Junk Food”: Evidence for Anti-Inflammatory Activity. Nutrients 2018; 10(11): 1604 doi: 10.3390/nu10111604
|
16 |
Eunüs S. Ali, Nikolai Petrovsky. Calcium Signaling As a Therapeutic Target for Liver Steatosis. Trends in Endocrinology & Metabolism 2019; 30(4): 270 doi: 10.1016/j.tem.2019.02.005
|
17 |
Yujie Shi, Wenxiang Zhang, Yinlong Cheng, Chang Liu, Siyu Chen. Bromide alleviates fatty acid‐induced lipid accumulation in mouse primary hepatocytes through the activation of PPARα signals. Journal of Cellular and Molecular Medicine 2019; 23(6): 4464 doi: 10.1111/jcmm.14347
|
18 |
Farah D.R. Al-Baiaty, Aziana Ismail, Zarina Abdul Latiff, Khairul Najmi Muhammad Nawawi, Raja Affendi Raja Ali, Norfilza Mohd Mokhtar. Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents. Frontiers in Pediatrics 2021; 9 doi: 10.3389/fped.2021.667247
|
19 |
Kiyoon Min, Abhishek Sahu, Sae Hyun Jeon, Giyoong Tae. Emerging drug delivery systems with traditional routes – A roadmap to chronic inflammatory diseases. Advanced Drug Delivery Reviews 2023; 203: 115119 doi: 10.1016/j.addr.2023.115119
|
20 |
Bin Cheng, Ai-Zhen Zhou, Wen Ge, Xiao-Min Yao, Juan Wang, Daniel Dias Rufino Arcanjo. Mechanism of Huo-Xue-Qu-Yu Formula in Treating Nonalcoholic Hepatic Steatosis by Regulating Lipid Metabolism and Oxidative Stress in Rats. Evidence-Based Complementary and Alternative Medicine 2021; 2021: 1 doi: 10.1155/2021/6026319
|
21 |
Ahtshamullah Chaudhry, Jawad Noor, Saima Batool, Ghulam Fatima, Riwad Noor. Advancements in Diagnostic and Therapeutic Interventions of Non-alcoholic Fatty Liver Disease: A Literature Review. Cureus 2023; doi: 10.7759/cureus.44924
|
22 |
QIAN XU, JI WANG, FEIFEI CHEN, KAISU LIN, MINGAO ZHU, LEI CHEN, XIUMIN ZHOU, CHONG LI, HONG ZHU. Protective role of magnesium isoglycyrrhizinate in non-alcoholic fatty liver disease and the associated molecular mechanisms. International Journal of Molecular Medicine 2016; 38(1): 275 doi: 10.3892/ijmm.2016.2603
|
23 |
Hongcai Li, Jingjing Liang, Mengzhen Han, Zhenpeng Gao. Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review. Journal of Advanced Research 2025; 68: 43 doi: 10.1016/j.jare.2024.03.004
|
24 |
Nipun Bawiskar, Sourya Acharya, Sunil Kumar. Fatty liver disease - non alcoholic to metabolic - A transition of concepts!!. Journal of Family Medicine and Primary Care 2024; 13(8): 2857 doi: 10.4103/jfmpc.jfmpc_1863_21
|
25 |
Nadiah S. Alzahrani, Ghedeir M. Alshammari, Afaf El-Ansary, Abu ElGasim A. Yagoub, Musarat Amina, Ali Saleh, Mohammed Abdo Yahya. Anti-Hyperlipidemia, Hypoglycemic, and Hepatoprotective Impacts of Pearl Millet (Pennisetum glaucum L.) Grains and Their Ethanol Extract on Rats Fed a High-Fat Diet. Nutrients 2022; 14(9): 1791 doi: 10.3390/nu14091791
|
26 |
Safaa H. Mohamed, Abdelaaty A. Shahat, Mohamed R. Mohamed, Wagdy K. B. Khalil, Ahmed M. Salem, Abdel Razik H. Farrag, Hanaa H. Ahmed. Camellia sinesis leaves extract ameliorates high fat diet-induced nonalcoholic steatohepatitis in rats: analysis of potential mechanisms. Journal of Pharmaceutical Investigation 2021; 51(2): 183 doi: 10.1007/s40005-020-00500-0
|
27 |
Paul D. Berk, Elizabeth C. Verna. Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2016; 20(2): 245 doi: 10.1016/j.cld.2015.10.007
|
28 |
Aishwarya Venkatasubramanian, Anand Thiyagaraj, Vairamuthu Subbiah, Solaipriya Solairaja, Sangaran Arumugam, Satish Ramalingam, Sivaramakrishnan Venkatabalasubramanian. Ameliorative role of ellagic acid against acute liver steatosis in adult zebrafish experimental model. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 2021; 247: 109061 doi: 10.1016/j.cbpc.2021.109061
|
29 |
Amira M. Badr, Iman O. Sherif, Yasmen F. Mahran, Hala A. Attia. The Renin Angiotensin System in Cancer, Lung, Liver and Infectious Diseases. Advances in Biochemistry in Health and Disease 2023; 25: 179 doi: 10.1007/978-3-031-23621-1_10
|
30 |
Blanca Martínez Soriano, Antonio Güemes, Guillermo Pola, Azucena Gonzalo, Pilar Palacios Gasós, Ana C. Navarro, Roberto Martínez-Beamonte, Jesús Osada, José J. García. Effect of Melatonin as an Antioxidant Drug to Reverse Hepatic Steatosis: Experimental Model. Canadian Journal of Gastroenterology and Hepatology 2020; 2020: 1 doi: 10.1155/2020/7315253
|
31 |
Priya Handa, Akhila Vemulakonda, Kris V Kowdley, Misael Uribe, Nahum Méndez-Sánchez. Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis?. World Journal of Gastroenterology 2016; 22(31): 6965-6971 doi: 10.3748/wjg.v22.i31.6965
|
32 |
Omar E. Hegazi, Samer O. Alalalmeh, Ghala Rashid Humaid Alnuaimi, Moyad Shahwan, Ammar Abdulrahman Jairoun, Nasser M. Alorfi, Shaker A. Majrashi, Mustfa Faisal Alkhanani, Abdullah Alkhattabi, Mansour M. Alourfi, Faris A. Alsolami, Saeed Alsharif, Hatim Alshahrani. NAFLD and nutraceuticals: a review of completed phase III and IV clinical trials. Frontiers in Medicine 2023; 10 doi: 10.3389/fmed.2023.1227046
|
33 |
Jin Liu, Yinglin Yuan, Xia Gong, Liangke Zhang, Qin Zhou, Shengwang Wu, Xue Zhang, Jun Hu, Ge Kuang, Xinru Yin, Jingyuan Wan, Yonghua Yuan. Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice. International Immunopharmacology 2020; 80: 106208 doi: 10.1016/j.intimp.2020.106208
|
34 |
Neti Jayanti, Rozzana Said, Suhaidah Jofrry, Chee-Yan Choo. Mechanistic pathway of herbs in the amelioration of NAFLD: A systematic review. World Academy of Sciences Journal 2024; 6(4) doi: 10.3892/wasj.2024.245
|
35 |
Atilla Engin. Obesity and Lipotoxicity. Advances in Experimental Medicine and Biology 2017; 960: 443 doi: 10.1007/978-3-319-48382-5_19
|
36 |
Priscila Silva Figueiredo, Aline Inada, Melina Ribeiro Fernandes, Daniela Granja Arakaki, Karine Freitas, Rita Avellaneda Guimarães, Valter Aragão do Nascimento, Priscila Aiko Hiane. An Overview of Novel Dietary Supplements and Food Ingredients in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease. Molecules 2018; 23(4): 877 doi: 10.3390/molecules23040877
|
37 |
Mengjie Li, Zheng Zhang, Bin Yu, Siqiang Jia, Bo Cui. Lycium barbarum Oligosaccharides Alleviate Hepatic Steatosis by Modulating Gut Microbiota in C57BL/6J Mice Fed a High-Fat Diet. Foods 2023; 12(8): 1617 doi: 10.3390/foods12081617
|
38 |
Koichi Yabiku. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.768850
|
39 |
Ayala Wollman, Tehila Daniel, Tovit Rosenzweig. Sarcopoterium spinosum Inhibited the Development of Non-Alcoholic Steatosis and Steatohepatitis in Mice. Nutrients 2019; 11(12): 3044 doi: 10.3390/nu11123044
|
40 |
Ping Ma, Congyong Sun, Wenjing Li, Wenwen Deng, Michael Adu‐Frimpong, Jiangnan Yu, Ximing Xu. Extraction and structural analysis of Angelica sinensis polysaccharide with low molecular weight and its lipid‐lowering effect on nonalcoholic fatty liver disease. Food Science & Nutrition 2020; 8(7): 3212 doi: 10.1002/fsn3.1581
|
41 |
Laura Belloni, Silvia Di Cocco, Francesca Guerrieri, Abigail D. G. Nunn, Silvia Piconese, Debora Salerno, Barbara Testoni, Claudio Pulito, Federica Mori, Matteo Pallocca, Andrea Sacconi, Elisa Vivoli, Fabio Marra, Sabrina Strano, Giovanni Blandino, Massimo Levrero, Natalia Pediconi. Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-31835-2
|
42 |
Camille Houron, Dragos Ciocan, Nicolas Trainel, Françoise Mercier-Nomé, Cindy Hugot, Madeleine Spatz, Gabriel Perlemuter, Anne-Marie Cassard. Gut Microbiota Reshaped by Pectin Treatment Improves Liver Steatosis in Obese Mice. Nutrients 2021; 13(11): 3725 doi: 10.3390/nu13113725
|
43 |
Yeon Ju Kim, Sung Yun Park, Ju-Hee Lee. Berteroin ameliorates lipid accumulation through AMPK-mediated regulation of hepatic lipid metabolism and inhibition of adipocyte differentiation. Life Sciences 2021; 282: 119668 doi: 10.1016/j.lfs.2021.119668
|
44 |
Mah I Kan Changez, Maryam Mubeen, Monezahe Zehra, Inara Samnani, Aniqa Abdul Rasool, Anmol Mohan, Um Ul Wara, Usha Tejwaney, Vikash Kumar. Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review. Journal of International Medical Research 2023; 51(9) doi: 10.1177/03000605231197058
|
45 |
Jing Sun, Xiuli Jin, Yiling Li. OTUD7B inhibited hepatic injury from NAFLD by inhibiting K48-linked ubiquitination and degradation of β-catenin. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2025; 1871(1): 167555 doi: 10.1016/j.bbadis.2024.167555
|
46 |
Maximilian Joseph Brol, Felicitas Rösch, Robert Schierwagen, Fernando Magdaleno, Frank Erhard Uschner, Steffen Manekeller, Alexander Queck, Katharina Schwarzkopf, Margarete Odenthal, Uta Drebber, Maja Thiele, Philipp Lingohr, Andreas Plamper, Glen Kristiansen, Sophie Lotersztajn, Aleksander Krag, Sabine Klein, Karl P. Rheinwalt, Jonel Trebicka. Combination of CCl4 with alcoholic and metabolic injuries mimics human liver fibrosis. American Journal of Physiology-Gastrointestinal and Liver Physiology 2019; 317(2): G182 doi: 10.1152/ajpgi.00361.2018
|
47 |
Yang Zhan, Qiong Li, Tao Li, Qinqin Yu, Yingmeng Li, Xiaoying Cheng, Yong Sun, Xiaoya Wang, Fanghua Guo, Hua Zhang, Wenjun Liu. Lactobacillus plantarum P9 ameliorates dysfunctional immune and metabolic homeostasis along the gut–liver axis in a nonalcoholic fatty liver disease with low-grade colitis mouse model. Food Bioscience 2024; 61: 104613 doi: 10.1016/j.fbio.2024.104613
|
48 |
Tae Wook Kim, Wynn Thein, Chang Yell Shin, Uy Dong Sohn. Inhibitory effects of Humulus japonicus extract against hepatic injury in a diabetic rat model. Food Science and Biotechnology 2021; 30(7): 979 doi: 10.1007/s10068-021-00924-w
|
49 |
Kyong Kim, Gong Deuk Bae, Minho Lee, Eun-Young Park, Dong Jae Baek, Chul Young Kim, Hee-Sook Jun, Yoon Sin Oh. Allomyrina dichotoma Larva Extract Ameliorates the Hepatic Insulin Resistance of High-Fat Diet-Induced Diabetic Mice. Nutrients 2019; 11(7): 1522 doi: 10.3390/nu11071522
|
50 |
Wei Hong, Songsong Li, Liyan Wu, Beihui He, Jianping Jiang, Zhiyun Chen. Prediction of VEGF-C as a Key Target of Pure Total Flavonoids From Citrus Against NAFLD in Mice via Network Pharmacology. Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.00582
|
51 |
Jun-Ke Long, Wen Dai, Ya-Wen Zheng, Shui-Ping Zhao. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Molecular Medicine 2019; 25(1) doi: 10.1186/s10020-019-0085-2
|
52 |
Tiange Li, Han Gong, Biyuan Zhan, Xueying Mao. Chitosan oligosaccharide attenuates hepatic steatosis in HepG2 cells via the activation of AMP‐activated protein kinase. Journal of Food Biochemistry 2022; 46(5) doi: 10.1111/jfbc.14045
|
53 |
Maret G. Traber, Brian Head. Vitamin E: How much is enough, too much and why!. Free Radical Biology and Medicine 2021; 177: 212 doi: 10.1016/j.freeradbiomed.2021.10.028
|
54 |
Aysun Tekbas, Jutta Huebner, Utz Settmacher, Uta Dahmen. Plants and Surgery: The Protective Effects of Thymoquinone on Hepatic Injury—A Systematic Review of In Vivo Studies. International Journal of Molecular Sciences 2018; 19(4): 1085 doi: 10.3390/ijms19041085
|
55 |
Chang-hua Zhang, Bu-gao Zhou, Jun-qing Sheng, Yang Chen, Ying-qian Cao, Chen Chen. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. Pharmacological Research 2020; 159: 104984 doi: 10.1016/j.phrs.2020.104984
|
56 |
Seungho Choi, Hyun Jin Jung, Min Woo Kim, Ju-Hee Kang, Dongyun Shin, Yeong-Su Jang, Yeo Sung Yoon, Seung Hyun Oh. A novel STAT3 inhibitor, STX-0119, attenuates liver fibrosis by inactivating hepatic stellate cells in mice. Biochemical and Biophysical Research Communications 2019; 513(1): 49 doi: 10.1016/j.bbrc.2019.03.156
|
57 |
Anuradha Pandey, Priyank Raj, Santosh Kumar Goru, Almesh Kadakol, Vajir Malek, Nisha Sharma, Anil Bhanudas Gaikwad. Esculetin ameliorates hepatic fibrosis in high fat diet induced non-alcoholic fatty liver disease by regulation of FoxO1 mediated pathway. Pharmacological Reports 2017; 69(4): 666 doi: 10.1016/j.pharep.2017.02.005
|
58 |
Jie Zhou, Chi-Tang Ho, Piaopiao Long, Qilu Meng, Liang Zhang, Xiaochun Wan. Preventive Efficiency of Green Tea and Its Components on Nonalcoholic Fatty Liver Disease. Journal of Agricultural and Food Chemistry 2019; 67(19): 5306 doi: 10.1021/acs.jafc.8b05032
|
59 |
Caifeng Xie, Zhen Chen, Chengfu Zhang, Xin Xu, Jiangbo Jin, Weihua Zhan, Tianyu Han, Jianbin Wang. Dihydromyricetin ameliorates oleic acid-induced lipid accumulation in L02 and HepG2 cells by inhibiting lipogenesis and oxidative stress. Life Sciences 2016; 157: 131 doi: 10.1016/j.lfs.2016.06.001
|
60 |
Qiong Ou-Yang, Chun-xiao Xuan, Xue Wang, Han-qiong Luo, Jin-E Liu, Lan-lan Wang, Ting-ting Li, Yu-peng Chen, Jun Liu. 3-Acetyl-oleanolic acid ameliorates non-alcoholic fatty liver disease in high fat diet-treated rats by activating AMPK-related pathways. Acta Pharmacologica Sinica 2018; 39(8): 1284 doi: 10.1038/aps.2017.142
|
61 |
Ludovico Abenavoli, Marta Greco, Natasa Milic, Francesca Accattato, Daniela Foti, Elio Gulletta, Francesco Luzza. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients 2017; 9(8): 870 doi: 10.3390/nu9080870
|
62 |
Sayali Bhave, Han Kiat Ho. Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease. Biomedicines 2021; 9(12): 1776 doi: 10.3390/biomedicines9121776
|
63 |
Tessa Kennedy-Martin, Jay P. Bae, Rosirene Paczkowski, Emily Freeman. Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review. Journal of Patient-Reported Outcomes 2018; 2(1) doi: 10.1186/s41687-018-0052-7
|
64 |
Yo Muraki, Yukimasa Makita, Midori Yamasaki, Yuichiro Amano, Takanori Matsuo. Elevation of liver endoplasmic reticulum stress in a modified choline-deficient l -amino acid-defined diet-fed non-alcoholic steatohepatitis mouse model. Biochemical and Biophysical Research Communications 2017; 486(3): 632 doi: 10.1016/j.bbrc.2017.03.072
|
65 |
Hessah Al‑Muzafar, Kamal Amin. Thiazolidinedione induces a therapeutic effect on hepatosteatosis by regulating stearoyl‑CoA desaturase‑1, lipase activity, leptin and resistin. Experimental and Therapeutic Medicine 2018; doi: 10.3892/etm.2018.6563
|
66 |
Luana A. Biondo, Alexandre A. S. Teixeira, Karen C. de O. S. Ferreira, Jose C. R. Neto. Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin. Current Pharmaceutical Design 2020; 26(9): 932 doi: 10.2174/1381612826666200122124116
|
67 |
Jing Gao, Jiajia Song, Min Du, Xueying Mao. Bovine α-lactalbumin hydrolysates (α-LAH) attenuate high-fat diet induced nonalcoholic fatty liver disease by modulating hepatic lipid metabolism in C57BL/6J mice. Journal of Functional Foods 2019; 54: 254 doi: 10.1016/j.jff.2019.01.027
|
68 |
Mingzhe Zhu, Meng Li, Wenjun Zhou, Yang Yang, Fenghua Li, Li Zhang, Guang Ji. Qianggan extract improved nonalcoholic steatohepatitis by modulating lncRNA/circRNA immune ceRNA networks. BMC Complementary and Alternative Medicine 2019; 19(1) doi: 10.1186/s12906-019-2577-6
|
69 |
Luciana Mendes Araújo Borém, Daniela Fernanda Freitas, Amanda Souto Machado, Alanna Fernandes Paraíso, Bruna Viana Caldas, João Felício Rodrigues Neto, Juliana Pinto Lima, André Luiz Sena Guimarães, Alfredo Maurício Batista de Paula, Sérgio Henrique Sousa Santos. Angiotensin II type 1 receptor (AT1) blockade by Telmisartan attenuates hepatic steatosis in high-fat fed mice reducing Resistin, TRL4, and Myd88 expression. Egyptian Liver Journal 2022; 12(1) doi: 10.1186/s43066-022-00216-w
|
70 |
Yanxin Xiao, Yan Liu, Liwei Zhao, Yaru Zhou. Effect of 5:2 Fasting Diet on Liver Fat Content in Patients with Type 2 Diabetic with Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders 2022; 20(8): 459 doi: 10.1089/met.2022.0014
|
71 |
Ki-Kwang Oh, Haripriya Gupta, Raja Ganesan, Satya Priya Sharma, Sung-Min Won, Jin-Ju Jeong, Su-Been Lee, Min-Gi Cha, Goo-Hyun Kwon, Min-Kyo Jeong, Byeong-Hyun Min, Ji-Ye Hyun, Jung-A Eom, Hee-Jin Park, Sang-Jun Yoon, Mi-Ran Choi, Dong Joon Kim, Ki-Tae Suk. The seamless integration of dietary plant-derived natural flavonoids and gut microbiota may ameliorate non-alcoholic fatty liver disease: a network pharmacology analysis. Artificial Cells, Nanomedicine, and Biotechnology 2023; 51(1): 217 doi: 10.1080/21691401.2023.2203734
|
72 |
Durmuş Fatih BAŞER, Esra KÜPELİ AKKOL, Mehmet BOZKURT, İpek SÜNTAR, Turan CİVELEK. Hepatoprotective effect of pomegranate (Punica granatum l.) in a rabbit model of steatohepatitis. Kocatepe Veterinary Journal 2021; doi: 10.30607/kvj.991650
|
73 |
Marisa Pfohl, Nicholas A. DaSilva, Emily Marques, Juliana Agudelo, Chang Liu, Michael Goedken, Angela L. Slitt, Navindra P. Seeram, Hang Ma. Hepatoprotective and anti-inflammatory effects of a standardized pomegranate (Punica granatum) fruit extract in high fat diet-induced obese C57BL/6 mice. International Journal of Food Sciences and Nutrition 2021; 72(4): 499 doi: 10.1080/09637486.2020.1849041
|
74 |
Maureen Whitsett, Lisa B VanWagner. Physical activity as a treatment of non-alcoholic fatty liver disease: A systematic review. World Journal of Hepatology 2015; 7(16): 2041-2052 doi: 10.4254/wjh.v7.i16.2041
|
75 |
Peng Huang, Fei-zhou Huang, Huai-zheng Liu, Tian-yi Zhang, Ming-shi Yang, Chuan-zheng Sun. LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6. Metabolism 2019; 94: 1 doi: 10.1016/j.metabol.2019.01.018
|
76 |
Love Sharma, Divya Gupta, Sheikh Tasduq Abdullah. Thioacetamide potentiates high cholesterol and high fat diet induced steato-hepatitic changes in livers of C57BL/6J mice: A novel eight weeks model of fibrosing NASH. Toxicology Letters 2019; 304: 21 doi: 10.1016/j.toxlet.2019.01.001
|
77 |
Qingqing Yu, Yayun Liu, Yufei Wu, Yong Chen. Dihydrocurcumin ameliorates the lipid accumulation, oxidative stress and insulin resistance in oleic acid-induced L02 and HepG2 cells. Biomedicine & Pharmacotherapy 2018; 103: 1327 doi: 10.1016/j.biopha.2018.04.143
|
78 |
Yayun Liu, Lu Liao, Yong Chen, Fengmei Han. Effects of daphnetin on lipid metabolism, insulin resistance and oxidative stress in OA‑treated HepG2 cells. Molecular Medicine Reports 2019; doi: 10.3892/mmr.2019.10139
|
79 |
Patrice Lazure, Jeremy W. Tomlinson, Kris V. Kowdley, Paolo Magni, Raul D. Santos, Ginny Jacobs, Suzanne Murray. Clinical practice gaps and challenges in non‐alcoholic steatohepatitis care: An international physician needs assessment. Liver International 2022; 42(8): 1772 doi: 10.1111/liv.15324
|
80 |
Kazutoshi Murotomi, Shigeyuki Arai, Satoko Uchida, Shin Endo, Hitoshi Mitsuzumi, Yosuke Tabei, Yasukazu Yoshida, Yoshihiro Nakajima. Involvement of splenic iron accumulation in the development of nonalcoholic steatohepatitis in Tsumura Suzuki Obese Diabetes mice. Scientific Reports 2016; 6(1) doi: 10.1038/srep22476
|
81 |
Vian Ahmed Wasta Esmail, Mohammed Omer Mohammed, Marwan S.M. Al-Nimer. Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome. Arab Journal of Gastroenterology 2021; 22(1): 1 doi: 10.1016/j.ajg.2020.12.005
|
82 |
Jella-Andrea Abraham, Olga Golubnitschaja. Time for Paradigm Change in Management of Hepatocellular Carcinoma: Is a Personalized Approach on the Horizon?. Personalized Medicine 2016; 13(5): 455 doi: 10.2217/pme-2016-0013
|
83 |
Jian ZHOU, Sian XU, Yue ZHU, Xin LI, Ao WANG, Junfang HU, Li LI, Yan LIU. Inhibition of neuropilin-1 improves non-alcoholic fatty liver disease in high-fat-diet induced obese mouse. Minerva Endocrinology 2023; 48(2) doi: 10.23736/S2724-6507.22.03895-7
|
84 |
Wenwu Huang, Boyuan Shen, Xiumei Li, Tongcun Zhang, Xiang Zhou. Benefits of Combining Sonchus brachyotus DC. Extracts and Synbiotics in Alleviating Non-Alcoholic Fatty Liver Disease. Foods 2023; 12(18): 3393 doi: 10.3390/foods12183393
|
85 |
Jing Sun, Xiuli Jin, Xinhe Zhang, Birong Zhang. HMGA2 knockdown alleviates the progression of nonalcoholic fatty liver disease (NAFLD) by downregulating SNAI2 expression. Cellular Signalling 2023; 109: 110741 doi: 10.1016/j.cellsig.2023.110741
|
86 |
Runzhou Sun, Ruixin Xiao, Pengfei Lv, Feifei Guo, Yanling Gong, Meixing Yan. Pink Lotus Essential Oil and Alleviates on Free Fatty Acid Induced Steatosis in HepG2 Cells via PI3K/Akt and NF-κB Pathways. Journal of Oleo Science 2022; 71(1): 95 doi: 10.5650/jos.ess21228
|
87 |
Xin Sun, Yan Zhang, Meilin Xie. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease. Acta Pharmaceutica 2017; 67(1): 1 doi: 10.1515/acph-2017-0007
|
88 |
Tu Guifang, Gong Xiangwen, Yang Qinhe, Li Yuanyuan, Wang Guanlong, Liang Yinji, Zhang Yupei, Yan Haizhen, Lin Chunmei, Zhang Jinwen. Effects of extracts from soothing-liver and invigorating-spleen formulas on the injury induced by oxidative stress in the hepatocytes of rats with non-alcoholic fatty liver disease induced by high-fat diet. Journal of Traditional Chinese Medicine 2018; 38(4): 535 doi: 10.1016/S0254-6272(18)30885-9
|
89 |
Li Cao, Ying Wu, Wenwen Li, Zengmiao Zhang, Yaping Niu, Chenchen Li, Shaobin Gu. Cornus officinalis vinegar reduces body weight and attenuates hepatic steatosis in mouse model of nonalcoholic fatty liver disease. Journal of Food Science 2022; 87(7): 3248 doi: 10.1111/1750-3841.16178
|
90 |
Nikunja Kishor Mishra, Amiyakanta Mishra, Rosy Priyadarshini. Non-Alcoholic Fatty Liver Disease (NAFLD) and its Recent Therapeutic Strategies. Research Journal of Pharmacology and Pharmacodynamics 2023; : 119 doi: 10.52711/2321-5836.2023.00022
|
91 |
N. U. Ashraf, T. A. Sheikh. Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. Free Radical Research 2015; 49(12): 1405 doi: 10.3109/10715762.2015.1078461
|
92 |
Chan-Hee Jung, Bora Lee, Dug-Hyun Choi, Sang-Hee Jung, Bo-Yeon Kim, Chul-Hee Kim, Sung-Koo Kang, Ji-Oh Mok. Association of grade of non-alcoholic fatty liver disease and glycated albumin to glycated hemoglobin ratio in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 2017; 125: 53 doi: 10.1016/j.diabres.2016.12.017
|
93 |
Tong Lin, Li Li, Caijun Liang, Lisheng Peng, Weicheng Hu. Network Pharmacology-Based Investigation of the Therapeutic Mechanisms of Action of Danning Tablets in Nonalcoholic Fatty Liver Disease. Evidence-Based Complementary and Alternative Medicine 2021; 2021: 1 doi: 10.1155/2021/3495360
|
94 |
Wen-qian Jia, Tao-cheng Zhou, Jing-wen Dai, Zhen-ni Liu, Ya-fei Zhang, Dan-dan Zang, Xiong-wen Lv. CD73 regulates hepatic stellate cells activation and proliferation through Wnt/β-catenin signaling pathway. European Journal of Pharmacology 2021; 890: 173667 doi: 10.1016/j.ejphar.2020.173667
|
95 |
Everton Cazzo, José Carlos Pareja, Elinton Adami Chaim. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Medical Journal 2017; 135(3): 277 doi: 10.1590/1516-3180.2016.0306311216
|
96 |
Shilpa Sharma, Ashish Sharma, Rajinder Singh Chauhan.
Computational dissection through network pharmacology and structure-based analysis unravels mechanistic actions of bioactive compounds in a hepatoprotective herb,
Picrorhiza kurroa
for the treatment of NAFLD and NASH
. Journal of Biomolecular Structure and Dynamics 2024; : 1 doi: 10.1080/07391102.2024.2438358
|
97 |
Milena Georgieva, Charilaos Xenodochidis, Natalia Krasteva. Old age as a risk factor for liver diseases: Modern therapeutic approaches. Experimental Gerontology 2023; 184: 112334 doi: 10.1016/j.exger.2023.112334
|
98 |
Tulasi Yadati, Tom Houben, Albert Bitorina, Yvonne Oligschlaeger, Marion J. Gijbels, Ronny Mohren, Dieter Lütjohann, Princy Khurana, Sandeep Goyal, Aditya Kulkarni, Jan Theys, Berta Cillero-Pastor, Ronit Shiri-Sverdlov. Inhibition of Extracellular Cathepsin D Reduces Hepatic Lipid Accumulation and Leads to Mild Changes in Inflammationin NASH Mice. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.675535
|
99 |
Ruifeng Liang, Wenjing Ge, Bingjie Li, Weifeng Cui, Xiaofan Ma, Yuying Pan, Gengsheng Li. Evodiamine decreased the systemic exposure of pravastatin in non-alcoholic steatohepatitis rats due to the up-regulation of hepatic OATPs. Pharmaceutical Biology 2022; 60(1): 359 doi: 10.1080/13880209.2022.2036767
|
100 |
Jin-Zhi Wang, Hai-Xia Cao, Jian-Neng Chen, Qin Pan. PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease. World Journal of Clinical Cases 2018; 6(8): 167-175 doi: 10.12998/wjcc.v6.i8.167
|
101 |
Masato Hamasaki, Naoki Sakane, Kazuhiko Kotani. Nonalcoholic Fatty Liver Disease Risk and Proprotein Convertase Subtilisin Kexin 9 in Familial Hypercholesterolemia Under Statin Treatment. Nutrients 2024; 16(21): 3686 doi: 10.3390/nu16213686
|
102 |
Rong Yang, Huili Yang, Dansheng Jiang, Linyi Xu, Lian Feng, Yufeng Xing. Investigation of the potential mechanism of the Shugan Xiaozhi decoction for the treatment of nonalcoholic fatty liver disease based on network pharmacology, molecular docking and molecular dynamics simulation. PeerJ 2022; 10: e14171 doi: 10.7717/peerj.14171
|
103 |
Bo Guo, Shengzhe Yan, Lei Zhai, Yanzhen Cheng. LncRNA HOTAIR accelerates free fatty acid-induced inflammatory response in HepG2 cells by recruiting SRSF1 to stabilize MLXIPL mRNA. Cytotechnology 2024; 76(2): 259 doi: 10.1007/s10616-023-00614-x
|
104 |
Rahnuma Ahmad, Mainul Haque. Metformin: Beyond Type 2 Diabetes Mellitus. Cureus 2024; doi: 10.7759/cureus.71730
|
105 |
Pnina Fishman, Shira Cohen, Inbal Itzhak, Johnny Amer, Ahmad Salhab, Faina Barer, Rifaat Safadi. The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice. International Journal of Molecular Medicine 2019; doi: 10.3892/ijmm.2019.4364
|
106 |
Santhanam Sanjai Dharshan, Karthikeyan Ramamurthy, Salamuthu Kaliraj, Krishnan Manikandan, Vellapandian Chitra, Rajakrishnan Rajagopal, Ahmed Alfarhan, S.Karthick Raja Namasivayam, Muthu Kumaradoss Kathiravan, Jesu Arockiaraj. Combined effects of vitamin D3 and dioxopiperidinamide derivative on lipid homeostasis, inflammatory pathways, and redox imbalance in non‐alcoholic fatty liver disease in vivo zebrafish model. Biotechnology and Applied Biochemistry 2024; doi: 10.1002/bab.2666
|
107 |
Jiaping Zheng, Sijie Chen, Yuqing Cai, Su Lin, Sujie Ke, Libin Liu. Insufficient nocturnal sleep was associated with a higher risk of fibrosis in patients with diabetes with metabolic associated fatty liver disease. Therapeutic Advances in Endocrinology and Metabolism 2020; 11 doi: 10.1177/2042018820947550
|
108 |
Atilla Engin. Obesity and Lipotoxicity. Advances in Experimental Medicine and Biology 2024; 1460: 539 doi: 10.1007/978-3-031-63657-8_18
|
109 |
Swaytha Ganesh, Vinod K. Rustgi. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2016; 20(2): 351 doi: 10.1016/j.cld.2015.10.009
|
110 |
Cheng Ma, Cheng Wang, Yafang Zhang, Honglin Zhou, Yunxia Li. Potential Natural Compounds for the Prevention and Treatment of Nonalcoholic
Fatty Liver Disease: A Review on Molecular Mechanisms. Current Molecular Pharmacology 2022; 15(6): 846 doi: 10.2174/1874467215666211217120448
|
111 |
Gary Huang, Daniel F. Wallace, Elizabeth E. Powell, Tony Rahman, Paul J. Clark, V. Nathan Subramaniam. Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics. Biomedicines 2023; 11(10): 2809 doi: 10.3390/biomedicines11102809
|